Auxilium Announces Results From Phase III Trial That Show AA4500 Successful In Treating Dupuytren's Contracture - News
Auxilium Announces Results From Phase III Trial That Show AA4500 Successful In Treating Dupuytren's Contracture
Wed, 21 Feb 2007 02:00 PM EST
... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced the positive final results of an early Phase III study of its lead development product AA4500 in the treatment of Dupuytren's contracture, a disabling and recurring hand condition in which the joints contract, impairing patients' ability to straighten and move their fingers. [click link for full article] ...
Related Topics
- Clinical Trials
- Connective Tissue Disorders
- Antithrombin III
- Familial Dysautonomia
- Antithrombin
- Family Issues
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Scabies
- Elbow Injuries and Disorders
- Diabetes
- Amniocentesis
- Biopsy
- CK
- Adapalene Topical
- Dupuytren’s contracture
- Volkmann’s ischemic contracture
- Deformity of the arm, shoulder contracture or fibrosis (frozen shoulder)
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Dupuytren’s contracture